A Phase 3 interventional study of Veligrotug in Thyroid Eye Disease, sponsored by Viridian Therapeutics, Inc.. Completed at 50 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by Viridian Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Graves Ophthalmopathy with a site in United States — 12 open to participants now, 18 under way, 8 of them phase 3. Graves Ophthalmopathy · United States.
Among the 53 studies in Graves Ophthalmopathy with a site in United States, this one is the 3rd largest by enrollment of the 47 interventional ones that give a count, is one of 11 that started in 2024, is one of 21 in phase 3, and was the 34th registered.
199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.
Browse Graves Ophthalmopathy studies →12 of the 53 studies in Graves Ophthalmopathy with a site in United States are open now. Recruiting first, the newest first:
Minghui Pharmaceutical (Hangzhou) Ltd · Sites in United States
Ages 18–75
Minghui Pharmaceutical (Hangzhou) Ltd · Sites in United States
Ages 18–75
Sling Therapeutics, Inc. · Sites in United States
Ages 18+
Ethyreal Bio, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
Amgen · Sites in United States, Poland, Spain and 1 more country
Ages 18–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 14 · Phase 3 24 · Phase 4 5
First in 2006; this study’s year is marked. 11 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 231 is above the median of 63 across 146 interventional studies indexed under Graves Ophthalmopathy.
Median enrollment 84 across the 47 interventional studies, 100 across the 5 observational. Of the 33 that completed or were terminated, 17 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 53 have an industry lead sponsor. The 10 most frequent:
Viridian Therapeutics, Inc. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Viridian Therapeutics, Inc. has 9 studies filed under Graves Ophthalmopathy — fewer than ten, so there is no comparison to draw.
4 of the studies in Graves Ophthalmopathy with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06401044AmgenA Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease | 2027-01-06 |
| NCT07832136Viridian Therapeutics, Inc.An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab | 2027-04 |
| NCT07623837THYROSCOPE INC.Clinical Validation of AI-Based Quantitative Eye Movement Analysis From Smartphone 9-Gaze Videos (Glandy EOM) | 2027-06-30 |
| NCT07623993THYROSCOPE INC.Prospective Observational Study of Smartphone-Based AI Self-Monitoring During Non-Surgical Treatment for Thyroid Eye Disease (THYROSCOPE) | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 53 studies in Graves Ophthalmopathy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in participants with TED. The primary objective of this clinical trial is to evaluate the safety and tolerability of VRDN-001 in participants with TED.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 5 intravenous (IV) infusions of veligrotug 10 milligrams (mg)/kilogram (kg) at 3-week intervals for 12 weeks.
Drug: Veligrotug
Participants will receive 5 IV infusions of veligrotug 3 mg/kg at 3-week intervals for 12 weeks.
Drug: Veligrotug
5 infusions of veligrotug
Also known as: VRDN-001
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Through Week 15
An adverse event (AE) was defined as any untoward medical occurrence that developed or worsened in severity during the conduct of a clinical study and did not necessarily have a causal relationship to study drug. TEAE was defined as an AE occurring on or after the day of the first dose of study medication through the end of the study. A summary of all Serious Adverse Events (SAEs) and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Baseline through Week 15
Change From Baseline in Proptosis in the Study Eye as Measured by Exophthalmometer
Proptosis was defined as distance between the lateral orbital rim and the most anterior position of the cornea in millimeters (mm), measured using an exophthalmometer. Observed change from baseline in proptosis in study eye is reported. Missing data were not imputed.
Time frame: Baseline, Week 15
Number of Participants With TEAEs Through Week 52
An AE was defined as any untoward medical occurrence that developed or worsened in severity during the conduct of a clinical study and did not necessarily have a causal relationship to study drug. TEAE was defined as an AE occurring on or after the day of the first dose of study medication through the end of the study. A summary of all SAEs and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Baseline through Week 52
As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated. The primary and secondary safety analyses and secondary efficacy analysis were measured in the pre-specified study eye per individual participant.
| Milestone | Veligrotug 10 mg/kg | Veligrotug 3 mg/kg |
|---|---|---|
| Started | 173 | 58 |
| Received at least 1 dose of study drug | 173 | 58 |
| Completed | 141 | 46 |
| Not completed | 32 | 12 |
| Withdrew: Adverse event | 4 | 2 |
| Withdrew: Progressive disease | 0 | 1 |
| Withdrew: Withdrawal by subject | 14 | 5 |
| Withdrew: Failure to adhere to protocol requirements | 3 | 1 |
| Withdrew: Lost to follow-up | 11 | 2 |
| Withdrew: Other than specified | 0 | 1 |
An adverse event (AE) was defined as any untoward medical occurrence that developed or worsened in severity during the conduct of a clinical study and did not necessarily have a causal relationship to study drug. TEAE was defined as an AE occurring on or after the day of the first dose of study medication through the end of the study. A summary of all Serious Adverse Events (SAEs) and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Veligrotug 10 mg/kg | Veligrotug 3 mg/kg |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) Through Week 15 | 153 | 55 |
Proptosis was defined as distance between the lateral orbital rim and the most anterior position of the cornea in millimeters (mm), measured using an exophthalmometer. Observed change from baseline in proptosis in study eye is reported. Missing data were not imputed.
| mm | Veligrotug 10 mg/kg | Veligrotug 3 mg/kg |
|---|---|---|
| Change From Baseline in Proptosis in the Study Eye as Measured by Exophthalmometer | -2.3 ± 1.74 | -2.1 ± 1.42 |
An AE was defined as any untoward medical occurrence that developed or worsened in severity during the conduct of a clinical study and did not necessarily have a causal relationship to study drug. TEAE was defined as an AE occurring on or after the day of the first dose of study medication through the end of the study. A summary of all SAEs and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Veligrotug 10 mg/kg | Veligrotug 3 mg/kg |
|---|---|---|
| Number of Participants With TEAEs Through Week 52 | 159 | 55 |
Collected over Baseline through Week 52. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Veligrotug 10 mg/kg | 0/173 (0%) | 10/173 (5.8%) | 142/173 (82.1%) |
| Veligrotug 3 mg/kg | 0/58 (0%) | 3/58 (5.2%) | 47/58 (81%) |
| Event | Veligrotug 10 mg/kg | Veligrotug 3 mg/kg |
|---|---|---|
| Mesenteric panniculitisGastrointestinal disorders | 0/173 | 1/58 |
| Amylase increasedInvestigations | 0/173 | 1/58 |
| Lipase increasedInvestigations | 0/173 | 1/58 |
| Joint neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/173 | 1/58 |
| Cardiac failureCardiac disorders | 1/173 | 0/58 |
| Graves' diseaseEndocrine disorders | 1/173 | 0/58 |
| Endocrine ophthalmopathyEye disorders | 1/173 | 0/58 |
| Optic disc disorderEye disorders | 1/173 | 0/58 |
| Retinal haemorrhageEye disorders | 1/173 | 0/58 |
| Retinal tearEye disorders | 1/173 | 0/58 |
| Event | Veligrotug 10 mg/kg | Veligrotug 3 mg/kg |
|---|---|---|
| Muscle spasmsMusculoskeletal and connective tissue disorders | 77/173 | 17/58 |
| AmenorrhoeaReproductive system and breast disorders | 23/70 | 5/26 |
| FatigueGeneral disorders | 23/173 | 11/58 |
| HeadacheNervous system disorders | 30/173 | 5/58 |
| AlopeciaSkin and subcutaneous tissue disorders | 30/173 | 6/58 |
| DiarrhoeaGastrointestinal disorders | 19/173 | 9/58 |
| TinnitusEar and labyrinth disorders | 21/173 | 8/58 |
| Dry skinSkin and subcutaneous tissue disorders | 23/173 | 5/58 |
| OnychoclasisSkin and subcutaneous tissue disorders | 21/173 | 6/58 |
| Blood creatine phosphokinase increasedInvestigations | 18/173 | 5/58 |
Safety Population included all enrolled participants who received at least 1 IV infusion of study drug.
| Age, Continuous(years) | Veligrotug 10 mg/kg | Veligrotug 3 mg/kg | Total |
|---|---|---|---|
| Mean | 49.1 ± 12.99 | 50.3 ± 12.89 | 49.4 ± 12.95 |
| Sex: Female, Male(Participants) | Veligrotug 10 mg/kg | Veligrotug 3 mg/kg | Total |
|---|---|---|---|
| Female | 132 | 46 | 178 |
| Male | 41 | 12 | 53 |
| Ethnicity (NIH/OMB)(Participants) | Veligrotug 10 mg/kg | Veligrotug 3 mg/kg | Total |
|---|---|---|---|
| Hispanic or Latino | 31 | 13 | 44 |
| Not Hispanic or Latino | 132 | 38 | 170 |
| Unknown or Not Reported | 10 | 7 | 17 |
| Race/Ethnicity, Customized(Participants) | Veligrotug 10 mg/kg | Veligrotug 3 mg/kg | Total |
|---|---|---|---|
| Race — Asian | 17 | 4 | 21 |
| Race — Black or African American | 16 | 6 | 22 |
| Race — White | 119 | 39 | 158 |
| Race — American Indian or Alaska Native | 1 | 0 | 1 |
| Race — Unknown | 3 | 0 | 3 |
| Race — Other | 5 | 3 | 8 |
| Race — Not Reported | 8 | 6 | 14 |
| Race — Multiple | 4 | 0 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2024 to primary completion in May 2025, 11 months.
Results were first posted in Aug 2026, 1 year 3 months after primary completion. A results delay was requested in Apr 2026.
Of 29 phase 3 interventional studies under Graves Ophthalmopathy, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 25. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AVE1642
Viridian Therapeutics, Inc.